HM Payson & Co. trimmed its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 19.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,013 shares of the company’s stock after selling 237 shares during the period. HM Payson & Co.’s holdings in Denali Therapeutics were worth $85,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently bought and sold shares of DNLI. Marshall Wace LLP acquired a new stake in Denali Therapeutics during the first quarter valued at $359,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Denali Therapeutics during the 3rd quarter worth about $1,988,000. JPMorgan Chase & Co. lifted its holdings in shares of Denali Therapeutics by 26.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 308,854 shares of the company’s stock worth $11,211,000 after acquiring an additional 64,168 shares during the period. Great West Life Assurance Co. Can boosted its position in shares of Denali Therapeutics by 141.7% during the 3rd quarter. Great West Life Assurance Co. Can now owns 14,606 shares of the company’s stock valued at $87,000 after acquiring an additional 8,562 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Denali Therapeutics by 3.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 486,440 shares of the company’s stock valued at $17,430,000 after acquiring an additional 15,194 shares during the period. Institutional investors and hedge funds own 68.15% of the company’s stock.
Shares of Denali Therapeutics stock opened at $52.99 on Friday. The company has a market capitalization of $6.41 billion, a P/E ratio of -23.98 and a beta of 2.00. The business has a 50-day moving average of $60.86 and a two-hundred day moving average of $62.49. Denali Therapeutics Inc. has a 1 year low of $18.45 and a 1 year high of $93.94.
Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, February 25th. The company reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $2.00. Denali Therapeutics had a negative return on equity of 39.19% and a negative net margin of 968.59%. The business had revenue of $316.82 million during the quarter, compared to analysts’ expectations of $87.98 million. On average, equities research analysts expect that Denali Therapeutics Inc. will post -2.2 EPS for the current fiscal year.
A number of research analysts have issued reports on DNLI shares. TheStreet raised Denali Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 26th. HC Wainwright upped their price target on shares of Denali Therapeutics from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, March 4th. Morgan Stanley upped their target price on shares of Denali Therapeutics from $75.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 16th. JPMorgan Chase & Co. started coverage on shares of Denali Therapeutics in a report on Friday, January 8th. They issued a “positive” rating for the company. Finally, Zacks Investment Research upgraded Denali Therapeutics from a “sell” rating to a “hold” rating and set a $66.00 price objective on the stock in a research report on Friday, February 19th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Denali Therapeutics currently has a consensus rating of “Buy” and an average price target of $74.63.
In related news, COO Alexander O. Schuth sold 10,000 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, February 4th. The stock was sold at an average price of $67.84, for a total value of $678,400.00. Following the sale, the chief operating officer now owns 10,686 shares of the company’s stock, valued at approximately $724,938.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Steve E. Krognes sold 1,448 shares of the company’s stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $74.68, for a total value of $108,136.64. Following the transaction, the chief financial officer now directly owns 14,427 shares of the company’s stock, valued at approximately $1,077,408.36. The disclosure for this sale can be found here. Insiders have sold 2,516,163 shares of company stock valued at $163,263,822 in the last three months. 19.30% of the stock is owned by insiders.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease.
See Also: Initial Coin Offerings entail a high degree of risk
Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI).